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Abstract
The National Institute of Health has estimated that over 1 million new cancer cases will
occur yearly. Posttraumatic stress disorder (PTSD) is commonly associated with near
death experiences or traumatic events, such as cancer diagnosis and treatment. There is a
lack of knowledge and awareness by healthcare professionals in identifying PTSD in
cancer patients. In this population, PTSD symptoms often contribute to anxiety, and there
is no standardized protocol being used to screen these individuals for the trauma they are
facing or have faced. The purpose of this project was to develop a clinical practice
guideline for screening cancer patients for PTSD in a clinic population serving 20%
cancer patients. The stress theory developed by Lazarus and Folkman guided this project.
The project questions were to identify the most appropriate screening tool for PTSD in
cancer patients and recommend a clinical practice guideline to the clinic healthcare
providers. Five widely used PTSD screening tools were reviewed. Based on the project
question the Clinician Administered PTSD Scale was identified as the most appropriate
for this clinic setting and patient population. An expert panel consisting of 3 experienced
psychiatric nurse practitioners reviewed the proposed guideline using the AGREE II tool.
Using a scale of 1 (strongly disagree) to 7 (strongly agree), the team members agreed
with a score of 5 or higher in each domain with the proposed guideline. Utilization of this
guideline will promote a positive social change towards mental health awareness and
improve the quality of life for these patients and their families.
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Section 1: Nature of the Project
Introduction
Cancer is the name given to a collection of related diseases in the body in which a
person’s own cells begin to divide without stopping and spread into surrounding tissues
(National Institute of Health [NIH], 2019). About 1.2 million new cancer cases are
diagnosed annually in the United States (National Cancer Institute, 2019). Cancer-related
posttraumatic stress syndrome (PTSD) has been documented in patients with cancer.
PTSD is characterized by the inability to relax for fear that a trauma will return as well as
the avoidance of triggers associated with the trauma, such as certain part of town or a
certain smell. PTSD can also include reliving a traumatic event in nightmares and/or
flashbacks (NIH, 2019).
PTSD is positively associated with other indices of distress and reduced quality of
life and is often associated with risk factors such as prior trauma history, preexisting
psychiatric conditions, or poor social skills (Cardova et al., 2017). The DSM-5 has
included cancer-related stress as an implication for PTSD criteria (American
Psychological Association, 2013). Research by the American Cancer Society (2019)
supports psychosocial assessments on all cancer patients. Treatment of cancer-related
PTSD should be approached with caution and be informed by existing evidence-based
approaches for traumatic stress (CITE). Many patients are not referred for counseling or
do not accept referrals to psychology-oncology services to be assessed and treated
because high levels of sadness and anxiety are often perceived as “normal” reactions to
cancer diagnosis and treatment; therefore, mood, anxiety, and other psychological
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disorders are commonly mistaken for unexpected, “manageable” sadness and
preoccupation with the disease (Grassi, Spiegel, & Riba, 2017). Emotional instability can
cause these patients to question their spirituality, personal values, and existence as well as
put strains on their personal relationships (CITE).
Mental health complications can occur at time of diagnosis, during and after
cancer treatments, and at survivorship. The NIH (2019) reported that PTSD symptoms
vary for each patient; however, symptoms will typically develop within 3 months of a
traumatic event up to several months or even years later. Side effects of cancer and
treatments can significantly influence a patient’s psychological state, potentially causing
a patient to be more susceptible to developing PTSD during a traumatic event in the
diagnosis, treatment, or survivorship (Caruso et al., 2017). Kirch (2019), director of
quality of life and survivorship at the American Cancer Society, reported that screening
for PTSD helps cancer centers identify patients early on who may be particularly
vulnerable to lasting mental scars.
We just don’t do a good job in general in oncology for screening for PTSD or
even assessing anxiety and depression. Oncologists might have a hard time
figuring this out because they treat a lot of people, and many don’t report
psychiatric symptoms and screening needs to be one of the first steps. (Ganz,
2019, p. 5).
The accuracy of diagnosis requires the use of reliable and valid instruments. The
development of a clinical practice guideline (CPG) at the project facility that screens for
PTSD will help facilitate an appropriate treatment plan for these individuals, promoting
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optimal patient care. The purpose of this project was to provide healthcare providers with
a CPG that promotes the use of a reliable and valid PTSD screening tool for patients in a
variety of cancer situations.
Problem Statement
The setting of this Doctor of Nursing Practice (DNP) project was a private,
psychiatric clinic in the north central United States. This clinic provides psychological
and psychiatric services to both children and adults. This facility was an appropriate
setting for this project because it receives referrals for this population from primary care
and oncology providers. Estimates from the facility administration are that 1 out of 5 (or
20%) of patients at this clinic currently have or have been diagnosed with cancer at some
point in their life. This community has a large influx of cancer patients because it is
centrally located and has an oncology center. Healthcare providers at this facility are
expected to screen and manage patients with mental illness using the best evidence-based
practices. This facility screens cancer patients for depression with use of the PHQ9 at
every visit. The generalized anxiety tool, known as the GAD7, which screens for the four
most common anxiety disorders, is utilized when a cancer patient presents to the clinic
with a chief complaint of daily anxiety, panic episodes, and obsessive behaviors and/or
thoughts.
Common symptoms of PTSD that a cancer patient may exhibit when they are
unable to deal with trauma of having cancer include reminiscing about traumatic
experiences over and over, intrusive thoughts, avoiding anything that could remind them
of the traumatic event, difficulties with the control of their emotions, panic, intense
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fear/anxiety, nightmares, and an overall difficulty with sleep (CITE). The earlier PTSD is
diagnosed, the more successful treatment can be (CITE). If PTSD is left untreated for
long periods of time, certain symptoms can be exacerbated, and many areas of a patient’s
life are severely affected (NIH, 2019). This doctoral project holds significance for social
change by providing education, advances in nursing, and the practice goal of improving
patient outcomes and promoting positive social change.
Purpose Statement
Lack of knowledge and awareness by health professionals contributes to the
underdiagnosis of PTSD in cancer patients. Identification of cancer status and screening
for PTSD at the initial psychiatric evaluation and subsequence visits is a proactive
approach to ensure that this problem is addressed in this population. Chan et al. (2017)
conducted a research study that involved 469 cancer patients who had been diagnosed
with various types of cancer. All patients for their study were recruited within 1 month of
their diagnosis at the same oncology referral clinic. The participants in their study were
evaluated for PTSD symptoms first after 6 months following their cancer diagnosis, then
again after 4 years. Chan et al. discovered that nearly one fifth of the participants
experienced PTSD symptoms within a few months of their cancer diagnosis, and many of
these people continued to display PTSD symptoms 4 years after their diagnosis.
Healthcare providers caring for cancer patients must understand and detect PTSD
symptoms in their patients to provide optimal care. The project questions were:
1. Based on the current evidence, what is the most appropriate screening tool for
PTSD in cancer patients?
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2. Based on the evidence reviewed, what CPG recommendations should be made
to the clinic healthcare providers?
Providing a CPG to healthcare providers for cancer patients suffering from PTSD will
increase their confidence when caring for patients in this population. Early screening and
detection can help promote various treatments used in treated PTSD, ultimately
improving this population’s quality of life.
Nature of the Doctoral Project
For this project, I reviewed evidence accessed through the Walden University
Library, including from the CINAHL, Medline, ProQuest, Psych Info, PubMed, and
Google Scholar databases. Inclusion criteria included English language only peerreviewed resources published within the past 5 years. CPGs related to the topic were also
reviewed. Keyword search terms included PTSD, cancer and PTSD, psychological
impact of cancer, cancer, and cancer screenings for mental health. In this project, I
followed the guidelines set forth in the Walden University DNP Manual for Clinical
Practice Guideline Development. CPG development requires a systematic method with
inclusion and exclusion criteria to search the literature and grade the strength of evidence
(Moran, Burson, & Conrad, 2017). The Appraisal of Guidelines Research and Evaluation
(AGREE) II instrument provided the framework for the development of this guideline.
The AGREE II is both valid and reliable and consists of 23 key items organized within
six domains (AGREE Research Trust, 2019).
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Significance
The primary stakeholders for this doctoral project were the nursing staff and
clinicians at this practicum site. Other stakeholders included family members,
oncologists, and primary care clinicians. Early identification and management of PTSD
will reduce the burden on insurance companies and third-party payers. This guideline will
encourage early screening and interventions in this population in efforts to reduce costs
of mental health and medical care across the lifespan (see Bellmore, 2016). The
contributions of this doctoral project include recommendations from the review and
initiation of a CPG that allows for nurses and clinicians to identify, screen, and treat for
PTSD in this population. Ultimately, this guideline will promote social change by
improving the patient’s quality of life, family structure, and relationships as well as
promote mental health awareness for communities, patients, nursing staff, and clinicians.
“Mental illness-related stigma, including that which exists in the healthcare system and
among healthcare providers, creates serious barriers to access and quality care” (Knaak,
Mantler, & Szeto, 2017, p. 111).
I integrated scholarship into this project by conducting a thorough literature
review in order to evaluate and apply up-to-date evidence focusing on the improvement
of patient outcomes. The role of the DNP in scholarship, in relation to Essential III:
Clinical Scholarship and Analytical Methods for Evidence-Based Practice, includes
discovering and integrating knowledge through the examination and synthesis of
academic literature, integrating knowledge from other disciplines by giving meaning to
isolated facts, and applying new knowledge in the practice setting (American Association
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of Colleges of Nursing [AACN], 2006). The project also aligned with DNP Essential VI:
Clinical Prevention and Population Health for Improving the Nation’s Health, which
incorporates leadership from the DNP-prepared clinician to integrate evidence-based
clinical prevention and population health services for individuals, such as those suffering
from the psychological aspects of cancer (AACN, 2006).
Walden University’s (2019) School of Nursing provided a rigorous and culturally
relevant approach to educational programs, based on a scholar-practitioner model. This
project influenced social change by supplying clinicians with evidence that will help
them with the early identification of mental illness in cancer patients with the goal of
enhancing the quality of life for their patients and families. The recommendations from
this project supported providers with identifying, screening, and treating PTSD in this
population.
Summary
In Section 1, I introduced the current gap in knowledge regarding which screening
tools are the most effective for the early identification of mental illness amongst cancer
patients. The nature of the project and the importance to stakeholders were explored. The
significance of developing this CPG to nursing practice was also described. In Section 2,
I provide an in-depth discussion of the background and context of the doctoral project as
well as the role of the DNP student.
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Section 2: Background and Context
Introduction
The current screening procedure at a private psychiatric clinic in the north central
United States was to screen all cancer patients for depression with the PHQ9 tool as well
as the GAD7 when anxiety symptoms were of concern. Currently, cancer patients are not
screened for PTSD even though current literature indicates that PTSD in this population
is extremely prevalent. The project questions were:
1. Based on the current evidence, what is the most appropriate screening tool for
PTSD in cancer patients?
2. Based on the evidence reviewed, what CPG recommendations should be made
to the clinic healthcare providers?
In this section, I explored the concepts and model that framed the project. The
relevance to nursing practice are synthesized. I also described the local background and
context for the project and discussed my role in developing and presenting the CPG to
stakeholders.
Concepts, Models, and Theories
In this project, I used the stress theory, developed by Lazarus and Folkman, for
the development of this CPG. The framework of the stress theory integrates stress,
appraisal, and coping as they relate to how individuals react to psychologically stressful
situations and/or environments (CITE). This clinical assessment of an individual’s coping
reaction facilitates enhanced clinical decision-making on how best to intervene as well as
provide one possible clinical indication of who will engage in maladaptive or adaptive
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coping (Folkman & Moskowitz, 2000). In clinical practice, this theoretical framework
has been utilized in the assessment, intervention, and evaluation of an individual’s
psychological stress and coping responses (CITE). Stress theories provide nursing with a
framework through which to understand the effects that stress has on individual and how
the individual responds to stressful situations and life events (McEwen & Will, 2011).
For this project, the theory of stress, coping, and adaptation, created by Lazarus
and Folkman (1984), was used to help healthcare providers understand the effects of
stress and how a person responds to stress. Kato (2014) indicated the importance for
healthcare providers to understand the role of coping for optimal healthcare provider and
patient communication, interactions, and the ability to help patients learn and adapt to
their traumatic events. Lazarus (1984) stated that cognitive appraisal occurred when a
person considers two major factors that contribute to their response to stress: (a) the
threatening tendency of the stress to the individual and the assessment of resources
required to minimize, tolerate, or eradicate the stressor and the stress it produces (see
Figure 1).
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. In general, cognitive appraisal is divided into two types or stages: primary and
secondary appraisal (Kato, 2014).

Figure 1. Lazarus and Folkman’s theory of stress and coping.
Lazarus (1984) provided the following definitions for terms important for
understanding the theory of stress and coping:
•

Stress: The physiological response to threatening or challenging events in the
environment.

•

Coping: The process of spending conscious effort and energy to solve
personal and interpersonal problems.

•

Adaption: The change that takes place as a result of the response to a stressor.
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CPG development requires a systematic method with inclusion and exclusion
criteria to search the literature and grade the strength of evidence (Moran et al., 2017).
The AGREE II tool provided the framework for the development of this guideline.
Relevance to Nursing Practice
The development of an evidenced-based CPG that addresses PTSD in cancer
patients in a psychiatric care setting advances the field of nursing practice because it
addresses a clinical problem using current evidence and increases healthcare providers’
confidence when caring for patients in this population. Early screening and detection can
help promote varied treatments for PTSD, ultimately improving this population’s quality
of life. The lack of knowledge and awareness of healthcare professionals contributes to
the underdiagnosis of PTSD in cancer patients (Knaap et al., 2014). In the following
subsections, I review existing research on this practice problem.
PTSD
About 70% of people worldwide will experience a traumatic event; yet, the
lifetime prevalence of PTSD is only at 5% (Atwoli et al., 2015). Other researchers have
shown that 4%–55% of this population should have a cancer-related PTSD diagnosis
(Cordova, Riba, & Spiegal, 2017). Chan et al. (2018) reported a strong prevalence of
PTSD in cancer patients at both 6 months and 4 years following cancer diagnosis. Chan
et al. also reported that the overall rate of PTSD decreased with time from 21.7%
incidence at 6 months to 6.1% incidence at 4 years. Over one third of participants who
were initially diagnosed with PTSD had persisting or worsening PTSD symptoms within
4 years of cancer treatments (Chan et al., 2018). The greater social awareness and
understanding along with reduced mental health stigma associated with cancer will act as
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a protective factor against PTSD, with this effect lessening as the patient has more years
in treatment and follow up (Chan et al., 2018).
PTSD affects all aspects of a patient’s life, including self-image, relationships
with family and friends, spirituality, ability to work, etc. (Gold et al., 2012). Emotional
instability can cause patients to question their spirituality, personal values, and the
meaning of their existence, which can strain patient relationships with loved ones (Grassi
et al., 2017). Multiple studies have revealed that psychological distress, including cancerrelated PTSD, negatively impact patients’ health, treatment, and quality of life (CITE).
Because of these factors, it is important for healthcare providers to recognize the signs
and symptoms of PTSD in this population, including avoidant behaviors that may exhibit
themselves as missed appointments, failing to complete treatment, or withdrawing from
friends to avoid speaking about the cancer. Increased psychological distress is further
correlated with decreased radiation treatment compliance and overall survival (Chen et
al., 2017).
PTSD and Cancer Patients
Abbey et al. (2017) indicated an increase in the prevalence rates of cancer-related
PTSD and that prevalence rates seemed to vary widely based on the method of
assessment. This study revealed that self-report PTSD symptom measures yielded
prevalence estimates of clinically significant symptom levels ranging from 7.3% to
13.8%, depending on screening scoring method used. Investigations using more stringent,
clinician-administered structured diagnostic interviews for PTSD yielded a lifetime
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prevalence estimate of 12.6% and a current prevalence estimate of 6.4% (Abbey et al.,
2017).
In a nationwide cohort study that included all Danish-born residents of Denmark
from 1995–2011, Gradus et al. reported that
Standardized incidence ratios (SIR) were calculated, null associations were found
between PTSD and nearly all cancer diagnoses examined, both overall (SIR for
all cancers = 1.0, 95% confidence interval (CI) = 0.88, 1.2) and in analyses
stratified by gender, age, substance abuse history and time since PTSD diagnosis.
(p. 568)
Although research has shown that cancer-related PTSD often has a chronic
course, researchers have also demonstrated that mental health services are grossly
underutilized by this population (Kadan-Lottick et al., 2015). Vachon (2006) stated that
only 10% of cancer patients reporting levels of distress received any type of psychosocial
therapy. Kadan-Lottick et al. (2015) interviewed 251 patients with advanced cancer and
found that 55% of those with a major psychiatric disorder did not receive a psychiatric
referral; yet, 90% of all participants said they would seek psychiatric help if they were
aware they had an emotional problem.
Screening Tools for PTSD
The mental health screening tool that formed the basis of the CPG developed in
this DNP project was the patient questionnaire instrument used for screening of PTSD.
Selecting a screening tool and establishing a screening process are essential first steps,
but they are only the beginning of developing a distress-screening program (Kendall et
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al., 2012). Many positive screens will require an assessment by the appropriate
psychosocial professional to determine the frequency, intensity, duration, and functional
impact of the distress (CITE). The assessment may reveal the need for intervention and/or
referral, so after intervention, follow up and further evaluation are needed ensure that the
patient’s distress is minimized or eliminated (Kendall et al., 2012).
Zebrack et al. (2015) suggested that screening tools for psychosocial distress
should yield reliable and valid results and recommended that institutions adopt screening
tools that align with the needs of their patient population. The VA (2019) identified the
CAPS screening tool as the gold standard in PTSD assessments. Their rationale for this
statement was that the tool, with its structured interview, provided a categorical diagnosis
as well as a measure of the severity of PTSD symptoms as defined by DSM-IV. Table 1
depicts a description of the most widely used PTSD screening tools.
Table 1
Screening Tools
Screening
tools
PCL-5

Description

Pros

Cons

20-item self-report measure
that assesses the 20 DSM-5
symptoms of PTSD.

The PCL-5 is
part of a national
effort to establish
PTSD outcome
measures.
It is well validated,
and much include
one Checklist for
DSM-5. (PCL-5) is
one of the most
commonly used selfreport measures of
PTSD (VA, 2019)

The PCL-5 can be
completed in five
to seven minutes.

Monitors symptom change
during and after treatment,
Screens individuals for
PTSD, and make a
provisional PTSD diagnosis
(VA, 2019)

Self-survey,
patients may not be
honest.
can be scored in
different ways
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PCL-S

PCL-C

PC-PTSD

The PCL-S (specific) asks
about symptoms in relation
to an identified "stressful
experience." The PCL-S
aims to link symptom
endorsements to a specified
event (VA, 2019).

This screening tool
asks specific
questions geared to a
specific traumatic
event.

It is only related to
a specific event.

The PCL-C (civilian) asks
about symptoms in relation
to generic “stressful
experiences” and can be
used with any population.
This version simplifies
assessment based on
multiple traumas because
symptom endorsements are
not attributed to a specific
event. In many
circumstances it is advisable
to also assess traumatic
event exposure to ensure
that a respondent has
experienced at least one
event that meets DSM-IV
Criterion A (VA, 2019).

The PCL-C is a
shortened version
of the PTSD
Checklist Civilian
version (PCL-C)
(VA, 2019).

Professional
judgment is needed
when it is utilized
while generalizing
it in other clinical
settings or with
military members.

This tool was
designed for the
primary care
settings.

Patients may not be
honest.

The PC-PTSD is a screening
tool for Posttraumatic Stress
Disorder. This tool has four
questions and is designed
for clinical use. It is not
designed to give a definitive
diagnosis of PTSD, rather it
assesses whether a clinical
interview should be carried
out for PTSD, thus further
screening.

The PC-PTSD is a 4item screen that was
designed for use in
primary care and
other medical
settings and is
currently used to
screen for PTSD in
veterans at the VA.
The screen includes
an introductory
sentence to cue
respondents to

The screen does not
include a list of
potentially
traumatic events.

Patients may not be
honest.

This does not
diagnosis PTSD.
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CAPS

CAPS ask respondents to
endorse up to three
traumatic events to keep in
mind during the interview.
CAPS-5 requires the
identification of a single
index trauma to serve as the
basis of symptom inquiry.
Symptom severity ratings
are based on symptom
frequency and intensity.

traumatic events.
The authors suggest
that in most
circumstances the
results of the PCPTSD should be
considered
"positive" if a
patient answer "yes"
to any 3 items.
Those screening
positive should then
be assessed with a
structured interview
for PTSD.
CAPS-5 is a 30-item
questionnaire,
corresponding to
the DSM-5 diagnosis
for PTSD. The
language of the
CAPS-5 reflects
both changes to
existing symptoms
and the addition of
new symptoms
in DSM-5 (VA,
2019).
CAPS-5 asks
questions relevant to
assessing the
dissociative subtype
of PTSD
(depersonalization
and derealization),
but no longer
includes other
associated symptoms
(e.g., gaps in
awareness).

CAPS-5 items are
rated with a single
severity score.
Patient not being
honest, though
since this is
administered by a
trained professional
this becomes less
likely.
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Local Background and Context
The setting of this DNP project was private, psychiatric clinic in north central
United States. This clinic receives referrals for this population from primary care and
oncology providers. One out 5 patients at this clinic currently have or have been
diagnosed with cancer at some point in their life. Healthcare providers at this facility
currently screen cancer patients for depression with use of the PHQ9 at every visit. The
generalized anxiety tool known as the GAD-7, which screens for the four most common
anxiety disorders, was administered when a cancer patient presents to the clinic with a
chief complaint of daily anxiety, panic episodes, and obsessive behaviors and/or
thoughts. The use of a CPG at this project site will promote identifying, screening, and
treating mental illness in this population. Using a CPG will increase the awareness of
PTSD for their cancer patients, community, nursing staff, and clinicians.
Role of the DNP Student
The DNP nurse is often involved in the development of CPGs within a nursing
specialty (Walden University, 2019). Practice guidelines within a healthcare organization
or system provide a method to translate evidence into practice and improve outcomes
(CITE). The assessment of patient needs or scientific advances may generate the
development of practice guidelines that are informed by a systematic process of review of
evidence (CITE). In situations where the demand for practice change is quicker than the
pace of national guideline development, the dissonance may result in a need to develop
guidelines at the local healthcare organization (White, Dudley-Brown, & Terhaar, 2016).
The DNP nurse is a future leader of the professional team for evaluation of evidence and

18
development of a new CPG to meet the needs of this practice site and patients. My role in
this project was to explore current evidence on PTSD screening tools and develop a CPG
for recommendation to the facility.
Summary
In Section 2, I discussed the clinical site’s needs and how this project was
developed to meet them. Lazarus and Folkman’s (1984) stress theory and AGREE II
were discussed as the methodology and framework used for development of this
guideline. PTSD screening tools were also identified and evaluated. I identified my role
in this project as well. In Section 3, I discuss the collection and analysis of the gathered
evidence and my process for developing the guideline.
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Section 3: Collection and Analysis of Evidence
Introduction
Cancer is the name given to a collection of related diseases in the body in which
cells begin to divide without stopping and spread into surrounding tissues (NIH, 2019).
Cancer-related PTSD has been documented in many patients at various stages of cancer
(Cordova et al., 2017). The current screening procedure at private psychiatric clinic in the
north central United States was to screen all cancer patients for depression with the PHQ9
tool. When anxiety symptoms are of concern, the GAD7 tool was also administered.
Based on my experience at the clinic and reports from other providers, cancer patients
were not screened for PTSD even though evidence indicated that PTSD in this population
was extremely prevalent.
Practice-Focused Questions
The project questions were:
1.

Based on the current evidence, what is the most appropriate screening
tool for PTSD in cancer patients?

2. Based on the evidence reviewed, what CPG recommendations should be
made to the clinic healthcare providers?
Sources of Evidence
The goal of this project was to review current evidence and guidelines to develop
a CPG to recommend to a private, psychiatric facility. To complete the literature review
for this project, I searched for evidence using the following keywords: PTSD, cancer and
PTSD, psychological impact of cancer, cancer screenings for mental health, and clinical
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practice guidelines and PTSD. The Walden University Library was accessed to explore
the following databases: CINAHL, Medline, ProQuest, Psych Info, PubMed, and Google
Scholar. Inclusion criteria included English language articles that were from peerreviewed sources and published within the past 5 years.
Analysis and Synthesis
Step 1: Critically Appraise the Evidence
A critical appraisal of the literature on the topic led to 18 current articles. I
reviewed each article to determine if it was pertinent to this topic and came from a peerreviewed source. My analysis of each article included reviewing the background
information, study objectives, research method, limitations, conclusions, and references.
The search results included experimental studies, systematic reviews, peer-reviewed
articles by content experts, guideline development manuals, and two international CPGs.
Various authors indicated the need for effective screening and identification of mental
illness in cancer patients in all situations (CITE). The articles were reviewed using the
following criteria:
1. Author, date, and title,
2. Level of evidence
3. Analysis,
4. Conclusions, and
5. Implications for practice.
I also reviewed CPGs related to the topic. These guidelines were previously discussed in
Table 1.
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Step 2: Synthesize the Evidence from the Literature
I synthesized the evidence according to the levels of evidence indicated in Table
2.
Table 2
Hierarchy of Evidence Table
Type of Evidence

Level of
Evidence
I
II
III

Description

SR or meta-analysis
Synthesis of evidence from relevant RCTs
RCT
Experiments where subjects are randomized
Controlled trial
Experiments where subjects are nonrandomly
without
assigned to a group
randomization
Case-control or
IV
Comparison groups or observations of groups to
cohort study
predict or determine outcomes
SR of qualitative or
V
SR of Gathering data on human behavior or
descriptive studies
describing background on an area of interest
Qualitative or
VI
Gathering data on human behavior or describing
descriptive study
background on an area of interest
Expert opinion or
VII
Opinions of experts or consensus of experts
consensus
Adapted from: Fineout Overhold, E., Melnyk, B., Stillwell, S., & Williamson, K. (2010).
Critical Appraisal of the Evidence: Part 1. American Journal of Nursing, 110(7) pg. 48.
Level I. Abbey et al (2015) conducted a systematic review that provided a
synthesis of evidence that justified the need the further investigating of traumatic related
events associated to cancer. Zebrack, Kayser, Sundstrom, et al. (2015) addressed cancer
patients’ emotional and psychosocial needs. Vodermaier, Linden, and Siu (2009)
conducted a literature search that yielded 106 validation studies that described a total of
33 screening measures, particularly newly developed cancer-specific scales, for assessing
a patient for mental illness.
Level II. Cordova et al. (2017) focused on the screening options and treatment of
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cancer-related PTSD by reviewing existing evidence-based approaches for traumatic
stress.
Level III. Knaak et al. (2017) revealed that both patient and staff well-being and
is committed to combating stigma in patient care to promote mental health screenings.
Level IV. Monson et al, (2008) reported a significant need to screen cancer
patients for PTSD. Chan et al. (2017) indicated that one third of patients (i.e., 34.1%)
who were initially diagnosed had persistent or worsening PTSD 4 years later. The authors
also indicated that there is a need for early identification of this subset of patients who
have cancer with PTSD to design risk-targeted interventions.
Level V. Katzman & John (2018), revealed that screening for PTSD in cancer
patients should be identified and treated appropriately based on age, diagnosis, treatment,
and by comorbid symptoms. Grassi et al. (2017) examined some of the most significant
related mental health issues in cancer patients while focusing on recent advances in
psychosocial and psychopharmacological interventions as a part of a mandatory,
integrated, and comprehensive approach to psychiatric cancer care. DeSantis et al. (2014)
reported that it is important for clinicians to understand the unique medical and
psychosocial needs of cancer survivors and to proactively assess and manage these
issues. There are a growing number of resources that can assist patients, caregivers, and
healthcare providers in navigating the various phases of cancer survivorship (DeSantis et
al., 2014).
Level VI. Allen et al. (2018) conducted a cohort study that revealed that most
cancer survivors report negative consequences related to their cancer experience. Allen et
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al. emphasized that clinicians need the skills to recognize and treat PTSD and other
psychiatric disorders in this patient population. Caruso et al. (2017) examined some of
the most significant issues related to screening and the assessments of psychosocial
morbidity in cancer patients. Gradus et al. (2015) displayed evidence showing an
association between PTSD diagnoses and various forms of cancer in a nationwide study.
While French-Rosa, Moye, & Nail (2015) reported that mental health interventions that
specifically address cancer-related PTSD may improve the cancer patient’s recovery and
adaptation over time.
Level VII. Vachon (2006) focused primarily on the psychosocial distress and the
coping of cancer survivors who have completed their initial treatment and are now
disease free. Researchers continue to debate the value of such interventions. Staton,
Rowland, and Ganz (2015) described major psychosocial and physical sequelae facing
adults during periods of cancer and highlighted the need for PTSD screening. Kimerling,
Prins, Yeager, and Magruder (2010) recommended using a five-point screening system
when determining whether the improvement is clinically meaningful using the PCL from
the DSM-IV for PTSD screening.
Step 4: Develop Clinical Practice Guideline
The proposed CPG was:
1. Cancer patient referral from oncology and/or primary care provider.
Initial visit scheduled.
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2. Initial psychiatric evaluation at clinic to include screening of all cancer
patients regardless of stages/situations with the PHQ9 (i.e., depression
scale) and the GAD7 (i.e., anxiety scale)
3. Patient scores above 0 on PHQ9 even though GAD7 is normal: complete
PHQ9 and GAD7 each visit.
4. Any abnormal GAD7 results would require PTSD screening with the
CAPS screening tool.
5. Patient scores under 4 on PHQ9 and under 3 on the GAD7. Conduct
yearly PTSD screening with the CAPS screening tool unless there is a
change in status at subsequent visits.
6. Initiate guideline per facility protocol for treatment.
Step 5: Identify an Expert Panel
The expert panel included three, board-certified, psychiatric nurse practitioners.
All of the expert panel participants were currently working in the mental health field. All
panelists evaluated and treated patients with PTSD and had over 10 years of experience
in this field.
Step 6: Obtain Institutional Review Board Approval
The facility signed the site approval form for the CPG development project.
Step 7: Obtain Expert Panelists’ Signatures
Upon Walden Institutional Review Board approval# 09-27-19-0662380, the expert
panelists signed the form for anonymous questionnaires.
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Step 8: The Expert Panelists Will Review the Guidelines
The panelists used the AGREE II instrument and made recommendations for
revisions. Each panel member reviewed the proposed guidelines using the following
domains:
1. Scope and purpose,
2. Stakeholder involvement,
3. Rigor of development,
4. Clarity of presentation,
5. Applicability, and
6. Editorial independence (AGREE Research Trust, 2019).
Step 9: Identify Key Stakeholders and/or End Users
I presented the revised guideline to end users, stakeholders, and other experts for
further discussion on content and usability.
Step 10: Develop a Final Report
Step 11: Disseminate Final Report to Key Stakeholders
Summary
To address the gap-in-practice at a local psychiatric clinic, I formulated practicefocused questions regarding the use of PTSD screening tools and a CPG to help identify,
screen, and treat PTSD patients from the psychological trauma of cancer. In this project,
I followed the Walden University DNP Manual for Clinical Practice Guideline
Development. Through an exhaustive literature search, I identified that the early
screening for PTSD in cancer patients is needed to improve their quality of life and give
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them the necessary support to cope with this traumatic event. In the next section, I
describe the reviews and recommendations made by the expert panel as well as the
development of the final new practice guideline.
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Section 4: Findings and Recommendations
Introduction
The setting for this DNP project was a private, psychiatric clinic in the north
central United States providing psychological and psychiatric services to both children
and adults. This facility has a large influx of cancer patients because it is centrally located
and has an oncology center. Healthcare providers at this facility are expected to screen
and manage patients with mental illness using the best evidence-based practices.
The purpose of this project was to provide healthcare providers with a CPG that
would promote treatment for PTSD for patients in a variety of cancer situations.
Developing a CPG addressed the gap in practice at the site and screening this population
for PTSD will help healthcare providers treat this population with evidence-based
practices. In Section 4, I describe the findings and recommendations from the expert
panel development of the new practice guideline. The project questions were:
1. Based on the current evidence, what is the most appropriate screening tool for
PTSD in cancer patients?
2. Based on the evidence reviewed, what CPG recommendations should be made
to the clinic healthcare providers?
Findings and Implications
In order to evaluate the validity of the created guideline, the recommended CPG
was appraised by an expert panel using the AGREE II tool. The expert panel consisted of
three psychiatric nurse practitioners working in mental health clinics. All panel members
had experience treating patients with PTSD. As previously mentioned, the AGREE II tool
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includes 23 criteria measures to appraise six domains as well as two, overall, global
rating assessment questions. Each question is rated on 7-point scale with 1 equating to
strongly disagree and 7 equating to strongly agree. Each domain score is summed by
totaling the scores of the individual items and dividing by the maximum possible score
(AGREE II Instrument, 2013). Table 4 describes the results of the expert panel AGREE
II tool reviews.
Table 4
AGREE II Expert Panel Results
Criteria

Review 1

Review
2

Review
3

Comments

1. The overall
objectives of the
guidelines were
specifically
described.

5

7

7

Improve quality of life
through accurate
screening and diagnosis
for the best evidencebased practice treatment.

2.Health questions
read the guideline
are specifically
described.

5

7

7

Appropriate, based on
current evidence with
best patient outcomes.

3. The population to
whom the guideline
is meant to apply is
specifically
described.

6

7

7

Children and adults,
define ages.

4. The guideline
development group
includes individuals
from all relevant
professional groups.

6

7

7

5. The views and
preferences of the

6

7

7

CAPS is lengthy and may
need to be limited to
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target population
have been sought.

older adolescents and
adults. Without core
morbidities and or
cognitive or intellectual
disorders.

6. The target users of 6
the guideline are
clearly defined.

7

7

7. Systemic methods
were used to search
for evidence.

6

7

7

8. The criteria for
selecting evidence
are clearly
described.

6

7

7

9. The strength and
limitations of the
body of evidence are
clearly described.

4

7

7

10. The methods for
formulating the
recommendations
are clearly
described.

5

7

7

11. The health
5
benefits, side effects,
and risks have been
considered in
formulating the
recommendations.

7

7

Risk with screening, no
risk patient information,
IRB approved, health
benefit, yes.

12. There is an
explicit link between
the
recommendations

7

7

Fix your general
audience, it may be
helpful to explain further
why you selected the

6

Adults, defined his age to
age without
neurocognitive disorders?
Ability to accurately
respond to screening?

Strength assist with
treatment; I know into
current evidence-based
practice limitations or
length of time. Provide
accurate screening, adapt
by other professionals.
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and supporting
evidence.

CAPS tool over other
screening tools.

13. The guideline
has been externally
reviewed by experts
prior to its
publications.

4

7

7

Yes, currently occurring.

14. A procedure for
updating the
guideline is
provided.

5

4

7

Utilizing expert panel
and clinic. Patient’s been
screened for feedback.

15. The
recommendations
are specific and
unambiguous.

5

7

16. The different
options for
management of the
condition or health
issue are clearly
presented.

4

Not
7
answered

Therapy, EMDR, SSRIs,
first, second, third, mind
treatment?

17. T
recommendations
are easily
identifiable.

4

7

7

Specific to screening,
yes.

18. The guideline
describes facilitators
and barriers to its
application.

5

7

7

Length of time to follow
clinical practice
guideline,
barrier/cognitive

Could you provide more
detail and how you
would or when you
would update the clinical
practice guideline?
7

Yes, however consider
how this may be different
with previous history of
anxiety/depression versus
new diagnostic
assessment and new
onset of symptoms
during, before, or after
cancer diagnoses and
treatment.
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status/previous mental
health diagnoses.
19. The guideline
6
provides advice
and/or tools and how
the
recommendations
can be put into
practice.

6

7

Yes, does the clinic need
to this weekly? Or allow
for extra time?

20. The potential
resource
implications of
applying the
recommendations
have been
considered.

4

7

7

Consider time to
administer screening, this
patient has time does the
provider have time?

21. The guideline
presents monitoring
and/or auditing
criteria.

6

7

7

Specific scoring
provided, more to
consider to be specific.

22. The views of the
funding body have
not influenced the
content of the
guideline.

7

7

7

23. Competing
interests of guideline
development group
members have been
recorded and
addressed.

7

7

7

Overall client
assessment

-

-

-

The CAPS take between
30 to 60 minutes to
complete could you
expand on who would be
trained to conduct this
assessment and how it
would fit in the daily
workload at the clinic.

-

32
1. Rate the overall
quality of this
guideline.

5

6

I would recommend
this guideline for
use.

Yes, with
Yes
modifications.

7

Yes

There needs to be
inclusion and exclusion
criteria including age,
health literacy/cognitive
ability and if prior history
depression anxiety and
personality disorder are
influencing factors or if it
will have different
screening criteria. Will
you be different
treatment approaches
depending on
screening/results?

Domain 1
Domain 1 of the AGREE II tool addressed the scope and purpose of the guideline
with three questions that focused on guideline objectives and the target population the
guideline will serve. The overall score for this domain was 91%, which reflects that the
objectives of the guideline were met. There were no questions or suggestions for
improvement in this domain from the expert panel. The purpose of the guideline was
specifically attained and the aim of the guideline, target population, and clinical concerns
were clearly identified.
Domain 2
Domain 2 of the AGREE II tool addressed stakeholder involvement with three
questions that focused on guideline creation participants, target users of the guideline,
and whether views and preferences of the target population were taken into consideration.
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The overall score for this domain was 91%, which reflects stakeholder involvement was
appropriate.
Domain 3
Domain 3 of the AGREE II tool addressed the rigor of development with eight
questions that focused on the search for evidence and the process used to formulate the
guideline recommendations. The overall score for this domain was 95%, reflecting that
the expert panel agreed to develop this guideline. No suggestions were offered in this
domain.
Domain 4
Domain 4 of the AGREE II tool addressed the clarity of presentation with three
questions that focused on guideline recommendations being specific and identifiable. The
overall score for this domain was 95%, reflecting a consensus that the guideline
presentation was easily understood.
Domain 5
Domain 5 of the AGREE II tool addressed the applicability of the guideline with
four questions that focused on barriers to implementing the guideline, guidance for
integrating it into practice, and the process for monitoring and auditing the guideline in
the future. The overall score for this domain was 95%, which reflects a consensus from
the expert panel. There were no suggestions offered.
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Domain 6
Domain 6 of the AGREE II tool addressed the editorial independence with two
questions that focused on the competing interests. The overall score for this domain was
91%, which was the highest scoring domain. No suggestions were offered.
Recommendations
All three experts completed a guideline assessment. The final overall score for the
quality of the guideline was 92.7% with all experts stating they would recommend the
guideline. One panelist recommended a modification related to length of provider
appointments for this screening; however, specific treatments for positive PTSD are not
necessarily addressed in this CPG because it is used to screen patients for PTSD. Again,
all expert panels agreed that they would use this guideline as recommended. My
recommended final CPGs are:
Step 1: Initial psychiatric evaluation at clinic to include screening of all cancer
patients regardless of stages/situations with the PHQ9 (i.e., depression scale)
and the GAD7 (i.e., anxiety scale).
Step 2: If patient scores above 0 on PHQ9, even though GAD7 is normal,
complete PHQ9 and GAD7 each visit.
Step 3: If any abnormal GAD7 results, require PTSD screening with the CAPS
screening tool.
Step 4: If patient scores under 4 on PHQ9 and under 3 on the GAD7, conduct
yearly PTSD screening with the CAPS screening tool unless there is a change in
status at subsequent visits.
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Step 5: Initiate the guideline per facility protocol for treatment. All providers
should to be culturally competent.
Strengths and Limitations of the Project
Having a CPG for PTSD screening will ensure that PTSD symptoms do not go
undiagnosed or treated. With early screening and detection of PTSD, healthcare providers
I developed this CPG specifically for the project site, so it may not be applicable to other
sites or specialties. Patients may not be honest when answering screening tools, which
may impact diagnosis and treatment. This CPG did not specify age recommendations for
the tool. Children and adolescent patients as well as patients with limited Englishspeaking ability might need different screening tools. Prior mental health diagnoses
would be taken into consideration but not necessarily guide this guideline. Clinicians
would be completing this guideline with patients. As mentioned by one of the panelists,
appointment times would need to be revised.
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Section 5: Dissemination Plan
For this scholarly project, I developed a CPG for PTSD screening specific to the
project site. An expert panel was created to evaluate the guideline. They used the AGREE
II tool and found it to be appropriate for implementation at the project site. Upon
receiving their positive evaluation, I presented the guideline to facility administrators. If
the project site decides to implement the guideline, I will assist with the education of staff
and implementation of the CPG. Another opportunity to disseminate the information
would be submitting it to other healthcare systems’ quality improvement teams. This
would allow the information to be disseminated to other local facilities in the area. A
final approach would be submitting the project manuscript for publication to an
appropriate nursing journal, which would broaden the audience to nationwide.
Scholar
I experienced personal and professional growth during the process of this project.
Completing this project allowed me the opportunity to work with a team member, both
on and off the project site. I learned that it is necessary to conduct an extensive literature
review to ensure that the most current evidence-based practices and data are reviewed
before developing a CPG. This experience has also provided me with the knowledge of
how to create a guideline and evidence of the positive effects it will have on this
population. As a DNP-prepared scholar, moving forward, I plan to participate in the
further development of CPGs.
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Practitioner
My growth as a practitioner has continued to increase throughout the journey of
completing my DNP degree. My own morals and values helped shape my desire to learn
more for my patients and ultimately provide optimal care. This care is based on
scholarship and research I have completed and the knowledge I have attained along the
way. My DNP project has helped me align my knowledge and skills with existing
theoretical frameworks to implement a new CPG and help develop better practices for the
improvement of patient care. This project has also helped me grow as a leader in nursing.
Project Manager
The creation of this guideline allowed me to be a project manager and
demonstrate my leadership ability as identified by the AACN (2006) DNP Essential II:
Organizational and Systems Leadership for Quality Improvement and Systems Thinking.
Walden University provided me with the skills and resources to manage this project from
start to end. My previous education as well as my personal and professional experiences
have helped shape and guide me as I completed a successful DNP project that is
applicable to the clinical setting.
Summary
The goal of this project was to identify a gap in nursing practice and develop an
evidence-based CPG to address it. This guideline could be placed into clinical practice
and have a positive effect on overall project site patient/resident outcomes and
readmission rates. The process of earning a DNP provided me with leadership
experience, confidence, and the knowledge to make a positive impact on patient care
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while promoting social change. While this is the terminal degree for my educational
process, I plan to continue my education working toward my PhD. I am so passionate
about nursing that I want to continue to share my knowledge, experiences, and expertise
with further generations as an instructor.
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